Bio Path Holdings Inc (NASDAQ:BPTH)
| 1.68 Delayed Data As of Mar 29 |  +0.03 / +1.83%Today’s Change | 1.27 Today|||52-Week Range 4.48 | +10.93% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $12.5M |
Company Description
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Contact Information
Bio-Path Holdings, Inc. 4710 Bellaire Boulevard Bellaire Texas 77401 |
Employees
Shareholders
| Other institutional | 4.41% |
| Mutual fund holders | 3.71% |
| Individual stakeholders | 2.05% |
Top Executives
| Peter H. Nielsen | Chairman, President, CEO, CFO & Treasurer |
| Ana Tari Ashizawa | Senior VP-Research, Development & Clinical Design |
| Anthony Price | Senior VP-Finance, Accounting & Administration |
| Douglas P. Morris | Secretary & Non-Independent Director |
| William F. Hahne | Vice President-Clinical Research |
